Adenocarcinoma of lung (disorder)
|
0.700 |
CausalMutation
|
disease |
CGI |
|
|
|
Adenocarcinoma of lung (disorder)
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Epidermal growth factor receptor gene expression in response to the tumor promoting phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) was analyzed in the A549 human lung adenocarcinoma cell line using DNA transfection.
|
2401353 |
1990 |
Adenocarcinoma of lung (disorder)
|
0.700 |
Biomarker
|
disease |
BEFREE |
Inhibition of tyrosine kinase activity decreases expression of surfactant protein A in a human lung adenocarcinoma cell line independent of epidermal growth factor receptor.
|
9060993 |
1997 |
Adenocarcinoma of lung (disorder)
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Co-expression of epidermal growth factor receptor and transforming growth factor-alpha is independent of ras mutations in lung adenocarcinoma.
|
10963846 |
2000 |
Adenocarcinoma of lung (disorder)
|
0.700 |
Biomarker
|
disease |
BEFREE |
On sections from both a human lung adenocarcinoma and a squamous cell carcinoma tissue microarray, fluorescence intensity for two epidermal growth factor receptors (EGFR and c-erbB2) correlates with diagnostic pathologic assessment, indicating that immunohistochemistry quantitation can be achieved.
|
12866417 |
2003 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
EGFR mutations were found in additional lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines.
|
15118125 |
2004 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The tight association with adenocarcinoma and the high frequency of mutations raise the possibility that EGFR mutations play an important role in the tumorigenesis of adenocarcinoma of lung, especially in East Asians.
|
15623594 |
2004 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We screened 60 lung adenocarcinomas defined as sensitive or refractory to gefitinib or erlotinib for mutations in EGFR and KRAS.
|
15696205 |
2005 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
CLINVAR |
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
|
15737014 |
2005 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
|
15737014 |
2005 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Inverse relationship between K-RAS and EGFR mutations in the lung adenocarcinoma was statistically significant (P=0.046, chi2 test).
|
15815931 |
2005 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
EGFR TK mutational analysis is a novel predictive test for selecting lung adenocarcinoma patients for targeted therapy with EGFR TK inhibitors.
|
15851406 |
2005 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Thus, analysis of EGFR tyrosine kinase mutations in lung adenocarcinoma is of clinical significance, as it can permit the customization of treatment with EGFR tyrosine kinase inhibitors.
|
15897572 |
2005 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Exons 19 and 21 of EGFR, the sites of hotspot mutations in lung adenocarcinomas, were screened in the 11 EGFR-amplified tumors but no mutations were found.
|
15920544 |
2005 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We examined the status of EGFR mutations in AAH and BAC to elucidate the role they play during multistage of lung adenocarcinoma.
|
15950315 |
2005 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the epidermal growth factor receptor tyrosine kinase domain in lung adenocarcinomas from Chinese patients were more frequent than reported previously in lung adenocarcinomas from American patients.
|
15958609 |
2005 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
To further investigate the prevalence of EGFR mutations in relation to ethnic and geographic factors, we evaluated EGFR mutations in a series of Taiwanese patients with primary lung adenocarcinomas who had never been treated with gefitinib.
|
16002952 |
2005 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The presence of EGFR mutations is a major determinant of gefitinib response, and EGFR tyrosine kinase inhibitors should be tested in clinical trials of first-line treatment of lung adenocarcinomas harboring EGFR mutations.
|
16011858 |
2005 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our patient supports the proposition that somatic mutation L858R in exon 21 of the EGFR gene accounts for complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung.
|
16027522 |
2005 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas.
|
16049312 |
2005 |
Adenocarcinoma of lung (disorder)
|
0.700 |
Biomarker
|
disease |
BEFREE |
The presence of EGFR mutations is a major determinant of gefitinib response, and targeting EGFR should be considered in preference to chemotherapy as first-line treatment in lung adenocarcinomas that have demonstrable EGFR mutations.
|
16115929 |
2005 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We conclude that mutations of the EGFR kinase domain and the cysteine-rich extracellular domains are infrequent in most types of human cancer apart from lung adenocarcinoma.
|
16133419 |
2005 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our findings indicate that mutation of the tyrosine kinase domain of EGFR is an early event in the pathogenesis of lung adenocarcinomas, and suggest EGFR mutations as an early detection marker and chemoprevention target.
|
16140919 |
2005 |
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Somatic mutations in the kinase domain of the epidermal growth factor receptor tyrosine kinase gene EGFR are common in lung adenocarcinoma.
|
16187797 |
2005 |
Adenocarcinoma of lung (disorder)
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
EGFR and HER2 gene amplification may be a late event and EGFR and HER2 protein expression may be associated with the development of adenocarcinoma of the lung.
|
16189154 |
2005 |